The certainty of the evidene is reduced by high or unclear risk of bias (blinding of participant and outcome assessor).
A Cochrane review [Abstract] 1 included 23 studies with a total of 2334 eyes. Bevacizumab, ranibizumab, conbercept, pegaptanib, and aflibercept were used. Anti-vascular endothelial growth factors (Anti-VEGFs) ± panretinal photocoagulation increased visual acuity compared with panretinal photocoagulation alone (mean difference (MD) -0.08 logMAR, 95% CI -0.12 to -0.04; 10 RCTS, 1172 eyes). Anti-VEGFs ± panretinal photocoagulation increased regression of new vessels (MD -4.14 mm2, 95% CI -6.84 to -1.43; I² = 75%; 4 RCTS, 189 eyes) and increased a complete regression of new vessels (RR 1.63, 95% CI 1.19 to 2.24; 5 RCTS, 405 eyes). Anti-VEGFs ± panretinal photocoagulation reduced vitreous haemorrhage (RR 0.72, 95% CI 0.57 to 0.90; 6 RCTS, 1008 eyes). Anti-VEGFs ± panretinal photocoagulation reduced the need for vitrectomy compared with eyes that received panretinal photocoagulation alone (RR 0.67, 95% CI 0.49 to 0.93; I8 RCTs, 1248 eyes).
Date of latest search: 2023-11-03
Primary/Secondary Keywords